Review

Dynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system

Bao Zhen Tan¹, Hua Huang¹, Runyi Lam¹ and Tuck Wah Soong*¹,²,³

Address: ¹Department of Physiology, Yong Loo Lin School Medicine, National University of Singapore, 117597, Singapore, ²Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA and ³National Neuroscience Institute, Jalan Tan Tock Seng, Singapore

Email: Bao Zhen Tan - g0601821@nus.edu.sg; Hua Huang - g0701801@nus.edu.sg; Runyi Lam - u0502827@nus.edu.sg; Tuck Wah Soong* - phsstw@nus.edu.sg

* Corresponding author

Abstract

The post-transcriptional modification of mammalian transcripts in the central nervous system by adenosine-to-inosine RNA editing is an important mechanism for the generation of molecular diversity, and serves to regulate protein function through recoding of genomic information. As the molecular players and an increasing number of edited targets are identified and characterized, adenosine-to-inosine modification serves as an exquisite mechanism for customizing channel function within diverse biological niches. Here, we review the mechanisms that could regulate adenosine-to-inosine RNA editing and the impact of dysregulation in clinical conditions.

Introduction

Nuclear pre-mRNA editing by selective adenosine deamination is catalyzed by a family of enzymes known as Adenosine Deaminases Acting on RNA (ADARs) [1], which results in a single nucleotide change from adenosine (A) to inosine (I). A-to-I editing is a dynamic and versatile post-transcriptional mechanism of single nucleotide recoding, which could drastically alter both the functional properties and expression levels of protein-coding mRNAs, increasing the repertoire of proteins available. Currently, most of the identified targets of A-to-I RNA editing are found in the mammalian nervous system, such as the ion channels and neurotransmitter receptors that play crucial roles in electrical excitability and signal transduction. Recoding of these proteins by RNA editing provides an attractive mechanism for customizing specific channel function within diverse biological niches, and any dysregulation of the process may contribute to the pathogenesis of certain diseases. Despite the tremendous amount of research invested in understanding the effects of RNA editing, how this activity is dynamically regulated remains unclear. In this review, we would discuss some potential mechanisms and factors that could dynamically regulate this A-to-I modification by ADAR, namely the expression and activity of ADAR family members via self-editing, alternative splicing and cross-talk between these two mechanisms. Environmental cues and other factors that modulate developmental and activity-dependent RNA editing will also be examined. In addition, some consequences of dysregulation in RNA editing in the nervous system will be discussed with regards to their clinical relevance.

RNA editing of ion channels and receptors alters their function and expression

Ion channels and neurotransmitter receptors in the mammalian nervous system are more common among the known targets of A-to-I RNA editing by ADARs [1]. Some
notable examples include a number of glutamate-gated ion channels, the voltage-gated K\(_{1.1}\) potassium channel, the GABA\(_{\gamma}\) receptor and the serotonin 5-HT\(_{2C}\) receptor. In almost all cases, A-to-I editing occurs at precise and functionally important locations in the protein, changing key amino acid residues crucial for the protein function [2]. Table S1 [see Additional file 1] summarizes the recoding of ADAR substrates by RNA editing, the amino acid position, and the physiological changes in channel properties and expression.

**Glutamate-gated ion channels**

A-to-I RNA editing of the glutamate-gated ion channels is the most extensively studied [3]. Five subunits of the glutamate receptor (GluR-B, GluR-C, GluR-D, GluR-5 and GluR-6) are found to undergo ADAR-mediated RNA editing [1]. Currently, a total of 4 editing sites that result in amino acid changes have been identified, namely glutamate to arginine (Q/R), arginine to glycine (R/G), isoleucine to valine (I/V), and tyrosine to cysteine (Y/C).

The first target of A-to-I RNA editing discovered in the mammalian system was the AMPA GluR-B subunit mRNA, in which a genomically encoded glutamine codon (CAG) was changed to an arginine codon (CIG) at position 607 [4]. This edited Q/R site, also found in the kainate receptor subunits GluR-5 and -6 [4], resides in the “pore loop region” of membrane segment 2 which determines the ion permeability of the glutamate channel [5]. Channels that contain the edited R form are less permeable to calcium [6]. However, for GluR-6, multiple editing at the Q/R, I/V and Y/C sites, located at positions 621, 567 and 571 respectively, may lead to higher calcium permeability [7]. Editing of the glutamate-gated ion channels at the R/G site changes an arginine (AGA) residue to glycine (GIA), resulting in an enhanced rate of recovery from receptor desensitization [8].

In most cases, editing is not 100% efficient and both the edited and non-edited isoforms co-exist in the cell. An interesting exception is editing of the Q/R site at the GluR-B subunits. In transgenic mice, failure to edit at this site leads to epileptic seizure and death within 3 weeks after birth [12].

**Voltage-gated Potassium channel**

Bhalla et al [13] reported that the mRNA transcript of human K\(_{1.1}\) undergoes A-to-I RNA editing, resulting in an amino acid change from genomic isoleucine to valine (GTT) [14]. As the hK\(_{1.1}\) gene is intronless, its exon-to-exon pairing forms the RNA duplex that is recognized by ADAR2. The A-to-I RNA editing occurs specifically at position 400 in the channel’s sixth transmembrane segment (S6), which lines the ion conducting pore. Electrophysiology analysis shows that the edited hK\(_{1.1}\) exhibits rapid recovery from fast inactivation as compared to the wild type channel.

Interaction of an inactivating particle with the pore of hK\(_{1.1}\) channel results in channel inactivation. The I-to-V amino acid change may disrupt this interaction, resulting in a faster recovery from inactivation [15]. Voltage-gated potassium channel plays an important role in the repolarization phase of the action potential. Therefore, changes in the inactivation kinetics will have an impact on the duration and frequency of the action potential. The faster recovery from inactivation shortens the duration of each action potential and increases the frequency of action potential [15]. To add to the complexity, potassium channels exist as tetramers, and each channel may contain different ratios of edited and unedited subunits. The physiological significance of the different extent of editing on the final properties of channel inactivation and the firing pattern of a neuron has yet to be determined.

**GABA\(_{\gamma}\) receptor**

The isoleucine codon (ATA) of the α3 subunit of the GABA\(_{\gamma}\) receptor is highly edited, resulting in a methionine codon (ATI) in the adult rat, mouse and human brains [16,17]. This I/M site resides in position 342 in the predicted third transmembrane domain of the α3 subunit. Functional analyses revealed that editing of this mRNA transcript results in GABA\(_{\gamma}\) receptors with smaller amplitudes, slower activation, and faster deactivation compared to the unedited receptor [17].

GABA\(_{\gamma}\) receptors are ligand-gated chloride channels, consisting of 5 subunits – 2 α subunits, 2 β subunits, and either a γ or δ subunit [18]. In the adult brain, activation of the GABA\(_{\gamma}\) receptors causes an influx of chloride ions, which produces an inhibitory current. However, during development, activation of the GABA\(_{\gamma}\) receptors produces an excitatory response, which is important for develop-
ment of the nervous system circuitry [19]. Editing of the α3 subunit is developmentally regulated – the edited GABAα receptors are expressed predominantly in the mature adult brain while the unedited receptors are mostly found in the developing brain [17]. Hence, RNA editing may regulate the function of the GABAα receptors during development – by allowing the expression of the non-edited GABAα receptors at the early stages, which play a crucial role in synaptic formation, followed by expression of the edited subunit in adulthood that is more suited to the inhibitory functions of GABAα receptors in action potentials.

**Serotonin 2C receptor**

The 2C subtype of serotonin receptor (5-HT2CR), a member of the G protein-coupled receptor superfamily, undergoes A-to-I RNA editing at five editing sites, named A, B, E (C0), C and D [20], causing amino acid changes from isoleucine to valine (I/V) at positions 157 and 161, isoleucine to methionine (M/I) at position 157, asparagine to serine (N/S), asparagine to aspartate (N/D) and asparagine to glycine (N/G) at position 159. Editing does not occur simultaneously at all five sites, and the differential combination of editing results in at least seven 5-HT2CR protein isoforms in rats [20] and at least 12 in humans [21]. Coincidentally, all five editing sites reside closely in the second intracellular loop of the receptor [20], which is responsible for its coupling to the G-protein [22]. Radioligand binding and functional studies of the edited isoforms showed a reduction in G-protein coupling and a lower level of constitutive activity, suggesting that RNA editing may be a novel mechanism for regulating neuronal excitability by stabilizing receptor signaling and enhancing the signal to noise ratio at serotonergic synapses [21].

**Family of Adenosine Deaminases that Act on RNAs (ADARs)**

Currently, three members of the ADAR family have been discovered in mammals, namely ADAR1, ADAR2 and ADAR3, according to the sequence of discovery. ADAR1 and ADAR2 were shown to be ubiquitously expressed, with enzymatic targets identified mainly in the nervous system while ADAR3 expression is restricted to brain and has yet no known targets [3,23]. ADARs work by recognizing partial or complete double-stranded RNA duplexes that are formed via base-pairing between the edited site and the editing-site complementary sequence (ECS), which is usually located in the downstream intron [24]. Although the mechanism of site-specific editing is incompletely understood, at least two studies have provided some insight into the roles of the multiple copies of double-stranded RNA binding motif (dsRBM). The dsRBM is a small motif of 75–85 amino acids, with the typical βαβαβαβ topology that forms a four stranded β-sheet packed against two α-helices [25]. ADAR1 contains three dsRBMs, and ADAR2 and ADAR3 each contains two dsRBMs in the amino (N) -terminus.

Full-length ADAR2 is unable to edit a 15-base pair RNA substrate harboring the R/G site of GluR-B, but this activity is restored when the N-terminal segment, including the dsRBM1 was deleted [26]. Furthermore, addition of the N-terminal segment in trans inhibits the recovery of editing activity, supporting the hypothesis that dsRBM1 inhibits the catalytic site of the enzyme. The study also implies that a minimum length requirement for the duplex RNA substrate exist, in order to engage both of the dsRBMs. Such a limitation would therefore restrict the editing specificity to RNA duplex structure of sufficient length. A second study reveals that the two dsRBMs of ADAR2 recognize different secondary structural elements of the RNA [27]. Via NMR-based model of the complex formed between ADAR2 protein and RNA encoding the R/G site, it is observed that while the dsRBM1 binds preferentially to the loop regions, the dsRBM2 recognizes two bulges in the stem region adjacent to the edited site (as shown in Figure 1). Therefore, recognition and binding of ADAR substrates by dsRBMs is structurally-dependent and length sensitive. In addition, multiple copies of dsRBMs and subtle amino acid changes among the different dsRBMs could allow preferential binding of ADAR family members to RNA substrates with different secondary structures.

Substrate specificity could also be defined by the deaminase domain of ADAR. Protein chimeras, in which the deaminase domains were exchanged between ADAR1 and ADAR2, retained the substrate specificity of the donor’s deaminase domain [28]. Although the crystal structure of ADAR2’s deaminase domain has been resolved, and the roles of zinc and inositol hexakisphosphate (IP6) as cofactors have been elucidated [29], the mechanism by which the catalytic site confers target specificity remains unknown.

ADAR proteins show exclusive nuclear localization and activity, with the exception of one splice variant of ADAR1, and edit the primary transcripts before splicing occurs [2]. While A-to-I editing in the coding region potentiates the generation of multiple RNA and protein isoforms from a single gene, editing in the untranslated regions may impact on other aspects of RNA functions such as splicing, mRNA stability and translation efficiency [30]. For example, editing in the intron may introduce alternative splice sites and could hence alter the reading frame.

**Regulation of ADAR activity by self-editing**

Both the pre-mRNA and mRNA of rat ADAR2 are susceptible to A-to-I editing, mediated by ADAR2 itself [30]. The
rADAR2 pre-mRNA self-editing occurs in intron 1 and exon 2, which comprise the hotspot of this gene, at six different editing positions, namely -2, -1, +10, +14, +23, and +24 [30,31]. Editing at position -1 in intron 1 converts an adenosine-adenosine (AA) dinucleotide to adenosine-inosine (AI), which mimics the canonical AG dinucleotides normally found at the 3’ splice junction [30]. The presence of AI thus acts as an alternative 3’ splice acceptor site, resulting in the retention of 47 nucleotides (nt) at +28 position of exon 1. This generates a frameshift and a truncated protein sequence with no editing activity, if translation starts at the first initiator methionine residue. Species differences is observed in the inclusion of 47-nt isoform in the brain, with an expression level of approximately 80% in mouse brain, while only around 15% of the ADAR2 transcripts in human brain has it [32]. In both species, the expression of the self-edited 47-nt isoform is more abundant in the brain than in the liver [32].

Alternatively, a downstream initiator methionine at amino acid position 25 in rat ADAR2 could be used to generate the functional protein for the self-edited isoforms [30]. However, in human ADAR2 proteins, the next methionine occurs only at position 84, which lies in the dsRBM1. Initiation of translation at this site may then compromise the RNA binding capacity of the expressed protein, and furthermore, may be inefficient and reduce protein expression. Transgenic mice lacking ADAR2 self-

Figure 1
Model of the conformational changes during ADAR2-mediated RNA editing. The deaminase domain is represented by the blue box; double-strand RNA binding motif (dsRBM), by the yellow boxes. In the absence of RNA, ADAR2 protein is inactive because the N-terminal domain prevents the association of dsRBMII and catalytic domain with substrate. In the presence of RNA substrate with specific secondary elements and sufficient length, conformational change frees up the catalytic domain, and allows both dsRBM and catalytic domain to bind to RNA substrate, as well as activation of enzyme. After the edited site is converted from A (in red) to a G (in red) by ADAR2, the RNA substrate is released for translation. (Figure adapted from Macbeth et al [26].)
editing express significantly higher levels of ADAR2, accompanied by increase in the editing levels of various ADAR2 substrates [33]. This implies that editing of its own pre-mRNA may thus serve as a negative feedback mechanism by which ADAR2 regulates its own expression activity.

**Regulation of ADAR activity by alternative splicing**

The human ADAR2 gene consists of 14 exons, with exons -2 and -1 located in the 5'-untranslated region (UTR) and exons 9 and 10 in the 3'-UTR [32]. In addition to retention of 47-nt via self-editing, multiple variations are also observed at the N-terminal via splicing, as indicated in Figure 2. In humans, the alternative inclusion of exon 1a adds 28 amino acids to the front of the commonly recognized initiator methionine residue. In comparison, the retention of exon 1b in mouse results in frame-shifting and early truncation of the protein [32]. Although it is proposed that alternative use of methionine in exon 1b may still result in the production of a functional protein, it is yet to be determined if the transcripts containing exon 1a or exon 1b could be expressed in vivo.

Maas and Gommans recently discovered a novel exon (exon 0) of mammalian ADAR2 located 18 kb upstream of exon 1, which extends the open reading frame by 49 amino acids [34]. Interestingly, the 49 amino acid extension harbors a sequence motif that is closely related to the R-domain of ADAR3, where it has been shown to function as a basic single-stranded RNA binding domain. Quantitative expression analysis shows that expression of the novel splice variant is tissue-specific, with the highest level in the cerebellum. In addition, the strong sequence conservation of the R-domain between human and rodent ADAR2 genes suggests a conserved function for this splice isoform.

Alternative splicing of exon 2 in the mRNA transcript of human ADAR2 could result in frame-shifting and an early stop codon in exon 3 [35]. In addition, the inclusion of an in-frame Alu sequence encoded by exon 5a in human ADAR2 reduces its catalytic activity by 50% [36]. In comparison, use of an alternative 3' splice acceptor site in intron 5 of mouse ADAR2 results in the inclusion of 30-nt Alu sequence and relatively higher catalytic activity [30].

---

**Figure 2**

**ADAR2 genomic structures for both human and mice.** Exons are represented by boxes; intron, by lines. Filled boxes are coding and open boxes are non-coding. # and * indicate the positions of potential initiator methionines and stop codons respectively. The grey box before exon 2 indicates the 47 nucleotide cassette, and A/G denotes the site of editing that creates the AG splice site. Alternatively spliced exons are indicated. The yellow box indicates the position of dsRBM, double stranded RNA binding domain while the green box indicates the position of catalytic domain. (Figure adapted from Slavov and Gardiner [32].)
Furthermore, use of the alternative splice site in exon 9 leads to a deletion of 29 amino acids from the carboxyl-terminal of human ADAR2 protein, resulting in a premature stop in exon 10. Such splicing event results in ADAR2 isoforms that have little editing activity on GluR-B mRNA [33]. Splicing in the 3' UTR of both human and mouse ADAR2 further contributes to the repertoire of ADAR2 proteins. Differential protein expression of C-terminal splice isoforms, detected by western blot, implies that such subtle splicing events could also play a role in regulating the translation efficiency of ADAR2 [35].

Cross-talk among ADAR1, ADAR2 and ADAR3

ADAR1 and ADAR2 have been shown to function as homodimer by both in vivo and in vitro experiments while the endogenous dimer formation of ADAR3 is also observed in mouse brain [14]. However, there is still controversy regarding interaction between the different ADARs to form heterodimers [14]. Overexpression of ADAR1 is shown to inhibit the editing activity of ADAR2 in pediatric astrocytoma, and ADAR1 could co-immunoprecipitate with ADAR2, suggesting a possible mechanism of inhibition via sequestering ADAR2 by ADAR1 in a heterodimer formation [37].

Formation of heterodimers between ADAR splice isoforms is shown to influence the overall editing efficacy. A reduction in RNA editing efficacy is observed in transgenic Drosophila expressing both wild type and inactive ADAR isoforms, which retains the binding to dsRNA substrates [38]. Although the structural details of interaction between two ADAR monomers are still unknown, the crystal structure of structurally similar cytidine deaminase APOBEC-1 homodimer has indicated that the active site in each monomer is completed only with contribution from the other partner [36]. Therefore, it is possible that a heterodimer of ADAR1 and ADAR2 may result in a non-functional enzyme that could neither edit ADAR1 nor ADAR2 substrates. In addition, the combination of splice variants of ADAR2 with low or no editing activities could also exert dominant negative effect via the formation of heterodimer with the wild type enzyme.

Furthermore, ADAR3 is observed to inhibit the activities of ADAR1 and ADAR2 in vitro, suggesting a possible role of ADAR3 in regulating the editing activity mediated by ADAR1 and ADAR2 [39].

Subcellular localization of ADAR1 and ADAR2

Subcellular localization of ADAR1 and ADAR2 proteins offers another intriguing aspect on the regulation of A-to-I editing efficacy. ADAR1 proteins, which shuttle between the nucleus and cytoplasm, contain a nuclear localization signal (NLS) located in the dsRBM3 [40] and a putative nuclear export signal (NES) in the N-terminal [41]. On the other hand, the activity of ADAR2 is restricted to the nucleus due to the single NLS in its N-terminal domain [42].

It is demonstrated by Desterro and co-workers that both ADAR1 and ADAR2 could be transiently sequestered into the nucleolus, a subnuclear region where transcription of ribosomal RNA (rRNA) occurs [41]. Local accumulation of small nucleolar RNAs (snRNAs) in the nucleolus may be responsible for the tethering of ADAR1 and ADAR2, due to interaction between these dsRNA structures with the dsRBD of ADAR. Enhanced translocation of ADAR2 to the nucleoplasm occurs upon the inhibition of rRNA synthesis or the presence of editing substrates in the nucleoplasm, which correlates with increased editing efficacy [42]. Such a model would therefore suggest that the editing substrates and snoRNAs compete for binding to the ADAR proteins. Hence, with accumulation of specific editing substrates in the nucleoplasm, the balance shifts and ADAR proteins are recruited to the nucleoplasm for A-to-I editing.

Developmental regulation of RNA editing

Editing of mRNA transcripts by ADAR enzymes is critical for normal life and development, as observed from the knockout mice that are deficient in either ADAR1 or ADAR2. ADAR2−/− knockout mice develop normally, but are prone to early onset of epilepsy and die within three weeks of birth. Underediting of the Q/R site in the GluR-B transcripts appears to be the underlying reason for the epileptic seizures, which could be rescued by introducing an edited version of GluR-B gene into the ADAR2−/− mice [43]. The deletion of ADAR1 in mice is embryonically lethal, and mice die between E11.5 and 12.5, as the mice develop a severe liver defect that involves cells of both the hematopoietic and hepatic lineages. Thus, ADAR1 appears to have a critical function in non-nervous tissues, which is likely to affect transcript editing [44].

Developmental analysis of known RNA editing substrates shows that editing of certain sites is regulated during the development of the brain. These would include mRNA transcripts of the AMPA and kainate members of the glutamate receptor family – GluR-B, GluR-5 & GluR-6 [33], the serotonin 5-HT2C receptor [45], the α3 subunit of GABA_A receptor [16,17], and ADAR2 itself [30]. Stimulation of calcium-permeable AMPA receptors steers differentiation of neural progenitor cells (NPCs) preferentially to neuronal cells, and promotes dendritic arborization. Overexpression of ADAR2 in NPCs results in Q/R editing and expression of calcium-impermeable AMPA receptors, which prevents AMPA-mediated differentiation, suggesting a physiological role for the Q/R editing process and the importance of unedited AMPA receptor subunits in neurogenesis [46]. While transition to edited AMPA corre-
lates with the overexpression of ADAR2, the exact mechanism and/or factors involved in regulation of RNA editing remain to be elucidated. Two studies tried to establish a correlation between ADAR mRNA expression level and editing frequency of 5-HT2C-R and GluR-B transcripts [45,47], but concluded that changes in expression level only is an insufficient model.

In the rat brain, both developmental and regional regulation of ADAR2 mRNA expression and splicing are observed [47]. Two splice variants of ADAR2, differing by the addition of a 30-nt Alu cassette, colocalize throughout the brain. While expression in the thalamic nuclei is the highest, the Alu-containing splice variant is more abundant overall. Interestingly, the expression of ADAR2 mRNA does not correspond temporally or spatially with its physiological substrates, GluR-B and 5-HT2C-R. A separate study by Hang et al finds that while expression level of ADAR2 mRNA markedly increases, that of ADAR1 mRNA remains constant during development [45]. During the embryonic period, ADAR2 pre-mRNA is unedited, but the number of edited sites and editing frequency increase after birth, suggesting that expression of edited ADAR2 may be significant to normal brain development. In addition, expression of ADAR1 and ADAR2 does not correspond with editing frequencies of specific target sites in the 5-HT2C-R mRNA. ADAR1 edits the A- and B-sites in 5-HT2C-R mRNA [48], while ADAR2 mediates editing of sites C and D [49]. Although the editing efficacies markedly increase during development, ADAR1 mRNA expression remains constant, suggesting that other factors may cooperate with ADAR1 such as RNA helicase [49,50].

Three models are proposed to help explain the mechanism behind the developmental increase in RNA editing [33]. First, ADAR1 and ADAR2 could be regulated at the post-transcriptional level such as protein modification or compartmentalization, which would enhance enzyme activity or its access to substrates. Second, the editing machinery may need a cofactor, which could synergistically enhance the actions of ADAR enzymes. Some potential candidates include the zinc ion, which coordinates and allows binding of ADAR2 to its pre-mRNA substrates, or the IP6, an inositol polyphosphate that binds and fills an extremely basic cavity in ADAR2 [29]. Third, access of ADAR enzymes to the editing sites may be controlled negatively by a competitive inhibitor. The 5-HT2C-R mRNA has significant sequence complementarity with a small nucleolar RNA, MBII-52, which specifically inhibits nucleolar editing [51], and the relative expression of MBII-52 may shift the balance of editing by trafficking or sequestering transcripts to specific compartments [52].

Hence, although the mRNA level of ADAR1 and ADAR2 may play critical physiological roles in the brain and peripheral tissues, changes in the expression of these enzymes alone could not account for the developmental regulation of RNA editing observed in the brain.

Activity-dependent RNA editing
RNA editing can be regulated by changes in metabolic activity, such as glucose concentration or serotonin level. Gan et al [53] reported an upregulation of ADAR2 transcripts and an increase in ADAR2-mediated editing of the GluR-B subunits in pancreatic β-islet cells exposed to physiological concentration of glucose, and the reverse occurred when the glucose concentration was decreased. Transient forebrain ischemia is caused by disruption of blood flow to the brain, causing a highly selective pattern of neuronal loss in the nervous system due to entry of toxic zinc and calcium ions into vulnerable neurons. In the setting of ischemia, heightened glycolysis could perturb glucose concentrations, leading to altered ADAR2 activity and editing. It is shown that forebrain ischemia in adult rats selectively reduces ADAR2 enzyme expression, and hence, disrupts editing of the Q/R site in GluR-B in vulnerable neurons [54]. Editing of this site determines the vulnerability of neurons in the rat hippocampus to forebrain ischemia. Expression of exogenous ADAR2 gene or a constitutively active CREB, which induces expression of endogenous ADAR2, results in recovery of Q/R editing in GluR-B and protection of vulnerable neurons in the rat hippocampus from this injury. In addition, ADAR2 gene silencing leads to degeneration of ischemia-insensitive neurons, and direct introduction of mutated gene, GluR-BQ607R prevents neuronal degeneration.

As mentioned above, the 5-HT2C-R pre-mRNA is edited at five closely-spaced adenosine residues located within the second intracellular domain of the receptor. The efficacy of editing at these sites is dependent on the serotonin level. Significantly decreased levels of editing at the C- and E-sites of 5-HT2C-R mRNA are observed in serotonin-depleted mice, leading to the expression of receptors with higher sensitivity to serotonin [55]. However, treatment with a 5-HT2A/2C agonist increases the editing frequency at the E-site and the expression of receptor that activates G-proteins least efficiently. Hence, changes in the editing status of 5-HT2C-R pre-mRNA could alter synaptic receptor activation and signaling bidirectionally depending on the receptor isofoms present.

Through the understanding of regulation of RNA editing in the physiological conditions, we could extend this knowledge into the study of pathophysiological conditions, and new treatment strategies that specifically target injured areas in the nervous system.
Consequences of RNA editing dysregulation

Dysregulation of RNA editing has been linked to many human diseases and recent studies have shown its importance in cancer [56]. Patients with glioblastoma multiforme (GBMs) have a reduction in both ADAR2 activity and editing of the GluR-B mRNA at the Q/R site [57]. Neuroplasm of glial cells represents the most common tumors of the CNS with GBMs being the most malignant [56]. Ishiuchi et al demonstrated that the Ca\textsuperscript{2+}-permeable non-edited GluR-B\textsuperscript{Q/R} promotes migration and proliferation of the glioblastomas, thus driving invasion and abnormal growth [58]. Expression of the edited GluR-B\textsuperscript{Q/R}, which is less permeable to calcium ion, prevents cell migration and induces cell death. Therefore, the Q/R site of the GluR-B is necessary for regulating migration of glioblastoma cells.

In a separate study, a correlation between reduction of ADAR2 editing activity and grade of astrocytomas is observed in children [37]. The authors also found that restoration of the ADAR2 editing activity in astrocytoma cell lines inhibit cell migration and proliferation. Using both bioinformatic approach and direct sequencing, considerable global hypoediting of Alu repetitive elements is observed in various tumors of the brain, prostate, lung, kidney, and testis [59]. Reduction of ADAR3 is found to correlate with the malignancy of GBMs. In addition, the mRNA levels of all 3 members of the ADAR family are reduced in brain tumors, most significantly in ADAR3. Overexpression of ADAR1 and ADAR2 in GBM cell line results in a decreased proliferation rate, suggesting that reduced A-to-I editing in brain tumors is involved in the pathogenesis of cancer [59].

Dysregulation of epigenetic mechanisms is recently shown to play a central role in pathogenesis of cancer. Interestingly, A-to-I RNA editing may serve as an additional epigenetic mechanism relevant to cancer development and progression. In the mammalian nervous system, ion channels are common targets of ADARs-mediated editing. Ion channels play an important role in controlling cell cycle and proliferation and alteration of their activities may facilitate cancer progression [60]. However, as neoplastic cells are genetically unstable and exhibit numerous altered biological pathways, it is debatable as to whether reduction in editing of ADARs substrates is the cause or just a consequence of tumor progression.

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures, due to neuronal hyperexcitability. The epileptic phenotypes observed in GluR-B editing-deficient mice are most profound and the severity of seizure activity correlates directly with the degree of impairment in editing of the Q/R position [61]. Although the molecular mechanism for epileptogenesis in these transgenic mice has not been elucidated, pre-editing of the GluR-B mRNA through genomic mutation rescues the seizure phenotype, suggesting that it is the changes in the AMPA channel properties that are the cause. A conditional mouse mutant where GluR-B editing is inactivated post-natally in selected forebrain regions supports the notion that unedited GluR-B directly causes neuron hyperexcitability, as editing deficiency in adult mice induces seizures with similarity to human temporal lobe epilepsy [62]. In contrast, elimination of GluR-B, which also results in Ca\textsuperscript{2+}-permeable AMPA receptors, does not elicit an epileptic phenotype in mice. Underediting of the Q/R site in Glu-R-B is critical because it not only determines AMPA receptors’ Ca\textsuperscript{2+} permeability, but also regulates gating kinetics, channel conductance, and channel assembly and trafficking. Epilepsy associated with GBM might also be linked to a decrease in GluR-B Q/R site editing [57].

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor neurons, resulting in progressive symptoms of muscle weakness, muscle atrophy, spasticity and eventually paralysis. Glutamate excitotoxicity appears to contribute to the pathology of sporadic ALS, whereby increase in glutamate levels suggest that prolonged activation of glutamate-gated ion channels might lead to excessive Ca\textsuperscript{2+} influx and neuronal death. The contribution of excessive Ca\textsuperscript{2+} influx through glutamate receptors to the death of motor neurons suggest that RNA editing might play a role in ALS. Editing at the Q/R position in GluR-B of spinal motor neurons from ALS patients were severely decreased, ranging from 62–100%, whereas all normal control cells showed 100% editing [63]. However, this deficiency in editing was not detected in motor neurons of rats transgenic for mutant human SOD1 (an animal model for familial ALS) or in patients with non-ALS motor neuron diseases, indicating that abnormal editing may be a contributory cause of neuronal death specifically in sporadic ALS. Again, it is not known when during the disease progression this impairment in editing arises or if it might be a causative event during the onset of ALS. Furthermore, this deficiency is only observed in spinal motor neurons, whereas upper motor neurons, which also degenerate in ALS, showed unaltered editing levels of GluR-B. This means that a defect in the Q/R site editing cannot be the sole mechanism responsible for the demise of the motor neurons. A recent genetic mouse model, whereby GluR-B subunits express the residue asparagine (N) at the Q/R position, results in channels with modestly increased Ca\textsuperscript{2+} permeability and late-onset motor neuron disease resembling the pathological changes observed in sporadic ALS [64]. Substantial increase in Ca\textsuperscript{2+} permeability of the AMPA receptors in principal neurons leads to early lethality precluding the observation of late-onset degenerative diseases. In addition, the GluR-B\textsuperscript{N} mutation accelerates disease progression and decrease survival in the background.
A-to-I editing of 5-HT2C R mRNA mediated by ADARs may be involved in mental disorders, and the increased understanding of the editing mechanism and target spectrum can explain some of the phenotypic features that result from RNA editing deficiency or hyperactivity. Owing to the functional implications of RNA editing, the ADAR enzymes may be targets for the pharmacological treatment of diseases of the central nervous system, such as depression, epilepsy, and schizophrenia.

Summary and outlook
RNA editing was once considered a rare peculiarity, and most studies in the mammalian brain have historically focused on just two editing targets, glutamate-gated ion channels and serotonin 2C receptors. However, a growing list of other brain editing targets has begun to overturn this initially limited view. RNA editing generates a diverse repertoire of proteins from a small fixed pool of genes that is able to fine tune and respond dynamically to rapid changes in the nervous system. Dysregulation of RNA editing results in irregular responses in the nervous system, some of which could even prove fatal [43]. Current understanding of the mechanisms underlying the regulation of RNA editing is still poorly understood and any correlations are still hypothetical. This review attempts to provide an insight to existing models of explanation – regulation of ADAR expression and activity by self-editing, alternative splicing and cross-talk among ADAR family members; developmental and activity-dependent regulation of A-to-I editing through environmental cues. Besides identifying new targets of A-to-I editing through bioinformatics, focus should be redirected to methodically examining the regulation of editing, as it seems to contribute significantly to both the physiological and pathophysiological conditions observed in the mammalian nervous system.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors participated in developing the ideas, the writing, discussion and integration of the information. All authors read and approved the final manuscript.

Additional material

Additional file 1
ADAR substrates with editing sites in coding sequence. The table summarizes currently known ADAR substrates with the editing sites named according to the amino acid change in the coding sequence, and the functional changes on the channel and receptor proteins.

Click here for file
[http://www.biomedcentral.com/content/supporting/1756-6606-2-13-S1.doc]
Acknowledgements
This work was supported by Singapore BioMedical Research Council to TWS (R-185-000-146-305).

References
1. Bass BL: RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002, 71:817-846.
2. Keegan LP, Gallo A, O'Connell MA: The many roles of an RNA editing enzyme. Nat Rev Genet 2001, 2:869-878.
3. Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, Seeburg PH: RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J Biol Chem 1996, 271:31795-31798.
4. Sommer B, Kohler M, Sprengel R, Seeburg PH: RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991, 67:11-19.
5. Seeburg PH, Single F, Kurer T, Higuchi M, Sprengel R: Genetic manipulation of key determinants of ion flow in glutamate receptor channels in the mouse. Brain Res 2001, 907:223-243.
6. Edgar J, Heiman-Sanchez SF: Cation permeability of edited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci USA 1993, 90:755-759.
7. Kohler M, Burnashev N, Sakmann B, Seeburg PH: Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron 1993, 10:491-500.
8. Lomeli H, Mosbacher J, Melcher T, Hoger T, Geiger JR, Kuner T, Monyer H, Higuchi M, Bach A, Seeburg PH: Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science 1994, 266:1709-1713.
9. Greger IH, Khati L, Ziff EB: RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum. Neuron 2002, 34:759-772.
10. Greger IH, Khati L, Kung X, Ziff EB: AMPA receptor tetrameration is mediated by Q/R editing. Neuron 2003, 40:763-774.
11. Widing TJ, Fulling E, Zhou Y, Huettner JE: Amino acid substitution in the pore helix of GluR6 control inhibition by membrane fatty acids. J Gen Physiol 2008, 132:85-99.
12. Brusa R, Zimprich A, Wimmer F, Koh DS, Feldmeyer D, Gass P, Seeburg PH, Sprengel R: Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995, 270:1677-1680.
13. Bhaila T, Rosenthal JJ, Holmgren M, Reenan R: Control of human potassium channel mRNA splicing by editing of a small mRNA hairpin. Nat Struct Mol Biol 2004, 11:950-956.
14. Cho DS, Yang W, Lee JT, Shiekhattar R, Murray JM, Nishikura K: Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J Biol Chem 2003, 278:17093-17097.
15. Bezanzilla F: RNA editing of a human potassium channel modifies its inactivation. Nat Struct Mol Biol 2004, 11:915-916.
16. Ohlson J, Pedersen JS, Haussler D, Ohman M: Editing modifies the GABA(A) receptor subunit alpha3. RNA 2007, 13:698-703.
17. Ruta EY, Lagrange P-A, Jacobs MM, Hu N, Macdonald RL, Emerson RB: Developmental modulation of GABA(A) receptor function by RNA editing. J Neurosci 2008, 28:6196-6201.
18. Hevers W, Luddens H: The diversity of GABA(A) receptors. Pharmacological and electrophysiological properties of GABA(A) types. Mol Neurobiol 1998, 18:35-86.
19. Ben-Ari Y, Gaarss J, Tyzio R, Khazipov R: GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 2007, 87:1215-1284.
20. Burns CM, Chu H, Rueret SM, Hutchinson LK, Canton H, Sanders-Bush E, Emerson RB: Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387:303-308.
21. Niswender CM, Copeland SC, Herrick-Davis K, Emerson RB, Sanders-Bush E: RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 1999, 274:9472-9478.
22. Pin JP, Joly C, Heinemann SF, Boackeia J: Domains involved in the specificity of G protein activation in phospholipase C-coupled metabolotropic glutamate receptors. EMBO J 1994, 13:342-348.
23. Wagner RW, Yoo C, Wraatze L, Kamholz J, Buchhalter J, Hassan NF, Khalili K, Kim SU, Perussi B, McConnell EA, et al: Double-stranded RNA unwinding and modifying activity is detected ubiquitously in primary tissues and cell lines. Mol Cell Biol 1990, 10:5586-5590.
24. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH: RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 1993, 75:1361-1370.
25. Maitaj IW: RNA recognition: a family matter? Cell 1993, 73:837-840.
26. Macbeth MR, Lingam AT, Bass BL: Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding. RNA 2004, 10:1563-1571.
27. Steff R, Xu M, Kriskovics L, Emerson RB, Allain FH: Structure and specific RNA binding of ADAR2 double-stranded RNA binding motifs. Structure 2006, 14:345-355.
28. Wong SK, Sato S, Lazinski DW: Substrate recognition by ADAR1 and ADAR2. RNA 2001, 7:846-858.
29. Macbeth MR, Schubert HL, Vandemark AP, Lingam AT, Hill CP, Bass BL: Nucleositol hexosamine binding to ADAR2 core and required for RNA editing. Science 2005, 309:1534-1539.
30. Rueter SM, Dawson TR, Emerson RB: Regulation of alternative splicing by RNA editing. Nature 1999, 399:75-80.
31. Dawson TR, Sansam CL, Emerson RB: Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J Biol Chem 2004, 279:4941-4951.
32. Slavov D, Gardiner K: Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns. Gene 2002, 299:83-94.
33. Lai F, Chen CX, Carter KC, Nishikura K: Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRAD2A double-stranded RNA adenosine deaminases. Mol Cell Biol 1997, 17:2413-2424.
34. Maas S, Gomanns WM: A novel exon of mammalian ADAR2 extends open reading frame. PLoS ONE 2009, 4:e4225.
35. Kawahara Y, Ito K, Ito M, Tsuji S, Kwak S: Novel splice variants of human ADAR2 mRNAs: skipping of the exon encoding the dsRNA-binding domains, and multiple C-terminal splice sites. Gene 2005, 363:193-201.
36. Gerber A, O'Connell MA, Keller W: Two forms of human double-stranded RNA-specific editase 1 (hrRED1) generated by the insertion of an Alu cassette. RNA 1997, 3:453-463.
37. Cenci R, Barzotti S, Galiano F, Corbelli S, Rosati R, Massimi L, Di Rocco C, O'Connell MA, Gallo A: Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem 2008, 283:7251-7260.
38. Gallo A, Keegan LP, Ring GM, O'Connell MA: An ADAR that edits transcripts encoding ion channel subunits functions as a dimer. EMBO J 2003, 22:3421-3430.
39. Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K: A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:753-767.
40. Eckmann CR, Neunteuffer A, Pfaffstetter L, Jantsch MF: The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol Cell Biol 2001, 11:1911-1924.
41. Destroer JM, Keegan LP, Lafort L, Berciano MT, O’Connell M, Carmo-Fonseca M: Dynamic association of RNA-editing enzymes with the nucleolus. J Cell Sci 2003, 116:1805-1818.
42. Sansam CL, Wells KS, Emerson RB: Modulation of RNA editing by functional nuclear subcellular localization of ADAR2. Proc Natl Acad Sci USA 2003, 100:14018-14023.
43. Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Sprengel R, Feldmeyer D, Sprengel R, Seeburg PH: Point mutation in an AMPA receptor gene renders it inactive in mice in vivo. J Biol Chem 1999, 274:9472-9478.
44. Hartner JC, Schmittwolf C, Kispert A, Muller AM, Higuchi M, Seeburg PH: Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem 2004, 279:4894-4902.
45. Hang PN, Tohda M, Matsumoto K: Developmental changes in expression and self-editing of adenosine deaminase type 2 pre-mRNA and mRNA in rat brain and cultured cortical neurons. Neurosci Res 2008, 61:398-403.
46. Whitney NP, Peng H, Erdmann NB, Tian C, Monaghan DT, Zheng JC: Calcium-permeable AMPA receptors containing Q/R-site unedited GluR2 directly human neural progenitor cell differentiation to neurons. FASEB J 2008, 22:2888-2900.

47. Paupard MC, O’Connell MA, Gerber AP, Zuki RS: Patterns of developmental expression of the RNA editing enzyme rADAR2. Neuroscience 2000, 95:869-879.

48. Liu Y, Emerson RB, Samuel CE: Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 1999, 274:18351-18358.

49. Seeburg Ph: RNA helicase participates in the editing game. Neuron 2000, 25:261-263.

50. Reenan RA, Hanrahan CJ, Ganetzky B: Altered adenosine-to-inosine RNA editing in human cancer. RNA Biol 2008, 5:135-139.

51. Mäkelä SH, Carrington CJ: RNA helicases encode a class of RNA editing enzymes that modulate gene expression. Curr Opin Genet Dev 2001, 11:97-103.

52. Werry TD, Loiacono R, Sexton PM, Christopoulos A: RNA editing of the serotonin 5HT2C receptor and its effects on cell signaling, pharmacology and brain function. Pharmacol Ther 2008, 119:7-23.

53. Maas S, Patt S, Scherer K: ADAR2-mediated editing of RNA substrates in the nucleus is inhibited by C/D small nuclear RNAs. J Cell Biol 2005, 169:745-753.

54. Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V: RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 2003, 87:1402-1412.

55. Seeburg Ph: RNA editing and alternative splicing of human serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002, 34:349-356.

56. Gallo A, Galardi S: A-to-I RNA editing and cancer: from pathology to basic science. RNA Biol 2008, 5:135-139.

57. Maas S, Patt S, Schrey M, Rich A: A To-I RNA editing and cancer: from pathology to basic science. RNA Biol 2008, 5:135-139.

58. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H: Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 2002, 8:971-978.

59. Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, Krupsky M, Ben-Dov I, Cazacu S, Mikkelsen T, Brodie C, Eisenberg E, Rechavi G: Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 2007, 17:1586-1595.

60. Kunzelmann K: Ion channels and cancer. J Membr Biol 2005, 205:159-173.

61. Krestel HE, Shimshek DR, Jensen V, Nevan T, Kim J, Geng Y, Bast T, Depaulis A, Schong K, Schwenk F, Bujard H, Hvalby O, Sprengel R, Seeburg Ph: A genetic switch for epilepsy in adult mice. J Neurosci 2004, 24:10568-10578.

62. Kwok S, Kawahara Y: Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. J Mol Med 2005, 83:110-120.

63. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell K, Yeat T, Upton N, Bromidge S, Forbes IT, Brown AM, Middleton DN, Blackburn TP: SB 240984 a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997, 36(4-5):659-620.